What is Unlearn.AI?
Founded in 2017 by former Pfizer principal scientist Charles Fisher, Unlearn.AI is a San Francisco-based pioneer in the application of digital twins within clinical research. The company's DiGenesis platform utilizes machine learning to generate longitudinal, computationally derived clinical records that simulate placebo control groups. By effectively replacing traditional placebo cohorts with these digital counterparts, Unlearn.AI aims to reduce the number of human participants required for trials, decrease variability, and enhance the statistical power of exploratory analyses. The firm is currently prioritizing high-impact therapeutic areas, specifically Alzheimer's disease and multiple sclerosis, where the need for efficient, evidence-based treatment pathways is most acute.
How much funding has Unlearn.AI raised?
Unlearn.AI has raised a total of $180M across 5 funding rounds:
Series A
$15M
Other Financing Round
$15M
Multiple Rounds
$150M
Series A (2020): $15M with participation from Mubadala Capital Ventures, Eisai, DCVC Bio, 8VC, and DCVC
Other Financing Round (2023): $15M led by Radical Ventures and Wittington Ventures
Series C (2024): $50M supported by Radical Ventures, Mubadala, Wittington Ventures, and Altimeter Capital
Series C (2024): $50M featuring Mubadala, Wittington Ventures, Radical Ventures, and Altimeter Capital
Series C (2024): $50M backed by Wittington Ventures, Mubadala, Radical Ventures, and Altimeter Capital
Key Investors in Unlearn.AI
Radical Ventures
A venture capital firm investing in bold entrepreneurs developing and applying artificial intelligence and other deep technologies to invent the future.
Mubadala
A global investment company based in Abu Dhabi with a mandate to create sustainable financial returns and foster a globally integrated economy.
Altimeter Capital
An investment firm that partners with technology companies from early growth through public markets, managing concentrated, long-term portfolios.
What's next for Unlearn.AI?
With the successful closure of its latest funding round, Unlearn.AI is well-positioned to accelerate the deployment of its DiGenesis platform across a broader spectrum of clinical applications. The strategic focus will likely shift toward expanding partnerships with global pharmaceutical entities and deepening the integration of its digital twin technology into standard regulatory submission processes. As the company moves beyond its initial development phase, the emphasis will remain on validating the efficacy of its models in complex, multi-site trials. Continued investment will be critical in maintaining the firm's competitive edge as it seeks to redefine the economics and speed of drug development through deep tech innovation.
See full Unlearn.AI company page
